Alpine Woods Capital Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Alpine Woods Capital Investors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,000	Closed	-$298K	–	472
2017 Q3	$298K	Sell	5,000 -2,000	-29%	-$121K	0.02%	372
2017 Q2	$552K	Hold	7,000	–	–	0.03%	290
2017 Q1	$581K	Hold	7,000	–	–	0.03%	295
2016 Q4	$555K	Hold	7,000	–	–	0.03%	297
2016 Q3	$490K	Hold	7,000	–	–	0.03%	311
2016 Q2	$272K	Hold	7,000	–	–	0.02%	362
2016 Q1	$284K	Hold	7,000	–	–	0.02%	360
2015 Q4	$621K	Buy	7,000 +2,000	+40%	+$158K	0.03%	303
2015 Q3	$370K	Buy	5,000 +1,000	+25%	+$83.2K	0.02%	361
2015 Q2	$323K	Buy	+4,000	New	+$261K	0.02%	377

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Woods Capital Investors's EGRX Position: Q4 2017 in Review

Alpine Woods Capital Investors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 5,000 shares — an estimated $298K sold.

Alpine Woods Capital Investors first reported a position in EGRX in Q2 2015 and held it in 10 quarters. The position peaked at $621K in Q4 2015. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

Alpine Woods Capital Investors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Alpine Woods Capital Investors sold 5,000 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $298K.
Alpine Woods Capital Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Alpine Woods Capital Investors's Eagle Pharmaceuticals, Inc. position peaked at $621K in Q4 2015.
170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2017, filed 14 Feb 2018.